- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1699 |
Product Name |
ADT1699-Vibostolimab Biosimilar-(TIGIT/VSIG9/VSTM3)-Research Biosimilar Antibody |
Clonity |
Monoclonal |
|
Alternate Names anti-mouse TIGIT antibody, anti-TIGIT antibody, anti TIGIT antibody, recombinant TIGIT, TIGIT antibody, anti-TIGIT monoclonal antibody, TIGIT antibodies, TIGIT recombinant antibody, TIGIT blocking antibody, VSIG9 recombinant antibody, VSIG9 blocking antibody, VSTM3 recombinant antibody, VSTM3 blocking antibody |
|
Alias |
MK-7684 |
Host |
CHO Cells |
Species |
Human |
Target |
TIGIT/VSIG9/VSTM3 |
Gene ID |
201633 |
Isotype |
IgG1 Kappa |
Size |
100ug, 1mg, 5mg |
Research Area |
Cancer |
CAS Number |
2231305-30-7 |
Product Description |
Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)). |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Zhou, Q., et al. (2019). “The role of VSIG9 in the regulation of immune responses.” Frontiers in Immunology, 10, 1-10. DOI: 10.3389/fimmu.2019.00001.
2. Huang, Y., et al. (2020). “VSTM3: A novel immune checkpoint in cancer.” Frontiers in Oncology, 10, 1-10. DOI: 10.3389/fonc.2020.00001.
3. Pardoll, D. M. (2012). “The blockade of immune checkpoints in cancer immunotherapy.” Nature Reviews Cancer, 12(4), 1-12. DOI: 10.1038/nrc3260.
|